Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
Subtype terms (8)
More specific conditions that are subtypes of Epilepsy in the MeSH hierarchy.
- Drug Resistant Epilepsy
46 drugs (34 approved, 12 experimental)
- Epilepsies, Partial
39 drugs (28 approved, 11 experimental)
- Epilepsy, Benign Neonatal
1 drug approved
- Epilepsy, Generalized
10 drugs (8 approved, 2 experimental)
- Epilepsy, Post-Traumatic
6 drugs (5 approved, 1 experimental)
- Epilepsy, Reflex
13 drugs (8 approved, 5 experimental)
- Epileptic Syndromes
4 drugs approved
- Sudden Unexpected Death in Epilepsy
5 drugs (4 approved, 1 experimental)
Drugs by status
Approved for this indication (37)
- piracetam
- acetazolamide
- brivaracetam
- lamotrigine
- clonazepam
- valproic acid
- perampanel
- ethosuximide
- felbamate
- gabapentin
- carbamazepine
- levetiracetam
- topiramate
- mistletoe
- mephenytoin
- safflower oil
- rufinamide
- diazepam
- vigabatrin
- zonisamide
- lacosamide
- midazolam
- phenazepam
- methylphenobarbital
- ethotoin
- metharbital
- methsuximide
- pentylenetetrazol
- phenacemide
- phensuximide
- +7 more
Phase 4 trials (28)
- nitrous oxide
- propofol
- vitamin d3
- norgestrel
- vitamin e
- procaine benzylpenicillin
- ketamine
- clevidipine
- clobazam
- prednisone
- methylphenidate
- cannabidiol
- sevoflurane
- escitalopram
- sertraline
- glycopyrronium
- idebenone
- ivermectin
- nitrazepam
- lidocaine
- immune globulin (human)
- risedronate
- stiripentol
- glucose
- dexmedetomidine
- pyridoxine
- sodium chloride
- gamma-aminobutyric acid
Phase 3 trials (30)
- metformin
- melatonin
- albendazole
- calcium carbonate
- carisbamate
- chlorpromazine
- progesterone
- folic acid
- ganaxolone
- haloperidol
- icosapent ethyl
- lorazepam
- lemborexant
- fluoxetine
- praziquantel
- saccharin
- everolimus
- tocilizumab
- carvedilol
- human fecal microbiota
- fentanyl
- bupropion
- naloxone
- chloral hydrate
- corn
- fenfluramine
- fish oil
- cenobamate
- phosphatidylserine
- lp352
Phase 2 trials (50)
- sumatriptan
- corticotropin
- buspirone
- alprazolam
- ibuprofen
- nifedipine
- gw273225
- ica-105665
- keishi-bukuryo-gan
- nimodipine
- vitamin c
- atorvastatin
- acetaminophen
- prochlorperazine
- naluzotan
- ataluren
- sirolimus
- acetylsalicylic acid
- cannabis
- Soticlestat
- talampanel
- anastrozole
- estradiol
- pentoxifylline
- triheptanoin
- natalizumab
- verapamil
- Vinpocetine
- vx-765
- huperzine a
- +20 more
Phase 1 trials (25)
Other trials (32)
- phenobarbital
- mppf
- urea
- carbon dioxide
- eslicarbazepine acetate
- ezogabine
- fosphenytoin
- nitrogen
- inulin
- primidone
- epinephrine
- levobupivacaine
- sodium butyrate
- ferumoxytol
- wuling
- alpha-lactalbumin
- fructo-oligosaccharide
- valpromide
- oxygen
- 15o water
- multivitamins
- pregabalin
- Sulthiame
- sodium bicarbonate
- technetium-99m bicisate
- minocycline
- lactase
- turmeric
- remifentanil
- apomorphine
- +2 more
Organizations
Organization Involved with Phase 4 Indications (96)
- The Medicines Company
- Forest Laboratories
- Pfizer
- Sanofi
- Bayer
- GlaxoSmithKline
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- Sunovion
- Yung Shin Pharm. Ind. Co., Ltd.
- IRCCS National Neurological Institute C. Mondino Foundation
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- National Institute of Mental Health (NIMH)
- University of Arizona
- Bangor University
- Azienda Ospedaliera San Gerardo di Monza
- California Medical Clinic for Headache
- Chulalongkorn University
- University of London
- Cornell University
- Harvard University
- Dong-A University
- Drexel University
- Hoosier Cancer Research Network
- Johns Hopkins University
- Korean Epilepsy Society
- McGill University
- Medical College of Wisconsin
- New York University
- Newcastle University
- +66 more
Organization Involved with Phase 3 Indications (83)
- Ache Laboratorios Farmaceuticos S.A.
- Ligand Pharmaceuticals
- Bausch Health Companies
- Grifols
- FGK Clinical Research GmbH
- Marinus Pharmaceuticals
- Neurelis, Inc.
- Parexel
- PTC Therapeutics
- Arvelle
- Xenon Pharmaceuticals Inc.
- Desitin Arzneimittel GmbH
- Nobel Pharmaceuticals
- Upsher-Smith Laboratories
- Zogenix, Inc.
- National Center of Neurology and Psychiatry, Japan
- National Institute of Neurological Disorders and Stroke (NINDS)
- Aarhus University
- University of Pennsylvania
- Cancer Research Network
- Centre Hospitalier St Anne
- Dartmouth University
- Emory University
- Hospital do Coracao
- Institut National de la Santé Et de la Recherche Médicale, France
- King Saud University
- Maharashtra University of Health Sciences
- Nanjing Medical University
- Scienze Neurologiche Ospedaliere
- The Canadian College of Naturopathic Medicine
- +53 more
Organization Involved with Phase 2 Indications (51)
- Vitaflo
- Acorda Therapeutics
- Jazz Pharmaceuticals
- Takeda
- Vertex
- AstraZeneca
- Biogen
- Alexza Pharmaceuticals, Inc.
- Baxalta
- Cavion LLC
- Cerebral Therapeutics LLC
- Neurocrine Biosciences
- Ovid Therapeutics Inc.
- PhytoTech Therapeutics, Ltd.
- Sponsor GmbH
- Yiling Pharmaceutical Inc.
- National Center for Complementary and Integrative Health (NCCIH)
- United States Army
- Ain Shams University
- Baylor University
- Georgetown University
- Katholieke Universiteit Leuven
- Neuroscience Trials Australia
- Oregon Health and Science University
- Radboud University
- Rijnstate Hospital
- University of Kansas
- The Epilepsy Study Consortium
- University of Calgary
- University of California, Davis
- +21 more
Organization Involved with Phase 1 Indications (18)
- Tilray
- Aadi, LLC
- Otsuka
- Polish Academy of Sciences
- University of Washington
- University of Lausanne
- University of Saskatchewan
- University of Alberta
- University of Utah
- SGS Life Sciences
- Vince & Associates
- Quotient
- Biotrial
- University of Mississippi
- Pharma Medica
- People's Liberation Army of China
- Advicenne Pharma
- Institution of Mother and Child, Warsaw, Poland
Organization Involved with Other Experimental Indications (30)
- GW Pharmaceuticals Ltd.
- Orphelia Pharma SA
- Dutch Epilepsy Clinics Foundation
- National Institutes of Health (NIH)
- Cook Children's Health Care System
- University of Pittsburgh
- American Academy of Neurology
- Augusta University
- Case Western Reserve University
- Geisinger Clinic
- McMaster University
- Menoufia University
- University of Florida
- University of Iowa
- University of Nebraska
- Fudan University
- University of Copenhagen
- Cook Children's Medical Center
- University of Toledo
- University of Ljubljana
- College of Physicians and Surgeons of Ontario
- National Research Agency, France
- Aix-University of Marseille
- James and Esther King Biomedical Research Program
- State of Georgia
- Shanghai Wu Mengchao Medical Foundation
- Shanghai Ankang Pharmaceutical Co.,LTD
- Citizens United for Research in Epilepsy
- National EpiFellows Foundation
- Fundación RiojaSalud